Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome

Clinical and Experimental Rheumatology

Volumn 33, Issue 3, 2015, Pages 443-444

  Meiners, P M ^a   Arends, S ^a   Meijer, J M ^a   Moerman, R V ^a   Spijkervet, F K L ^a   Vissink, A ^a   Bootsma, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EULAR SJOEGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; HUMAN; LETTER; MALE; MULTIDIMENSIONAL FATIGUE INVENTORY GENERAL FATIGUE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PATIENT GLOBAL DISEASE ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; SALIVATION; SERUM SICKNESS; SJOEGREN SYNDROME; VISUAL ANALOG SCALE; XEROSTOMIA; MIDDLE AGED; RECURRENT DISEASE; REMISSION; SJOGREN'S SYNDROME; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; RETREATMENT; RITUXIMAB; SJOGREN'S SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939490364     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. MEINERS PM, VISSINK A, KALLENBERG CGM et al.: Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin Biol Ther 2011; 11: 1381-94.
2. DEVAUCHELLE-PENSEC V, MARIETTE X, JOUSSE-JOUILIN S et al.: Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160: 233-42.
3. GOTTENBERG JE, CINQUETTI G, LARROCHE C et al.: Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and rituximab registry. Ann Rheum Dis 2013; 72: 1026-31.
4. CARUBBI F, CIPRIANI P, MARRELI A et al.: Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15: R172.
5. MEIJER JM, MEINERS PM, VISSINK A et al.: Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
6. MEINERS PM, ARENDS S, BROUWER E, SPIJKER-VET FK, VISSINK A, BOOTSMA H: Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012; 71: 1297-302.
7. SEROR R, RAVAUD P, BOWMAN SJ et al.: EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
8. MOERMAN RV, ARENDS S, MEINERS PM et al.: EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis 2014; 73: 472-4.
9. SEROR R, GOTTENBERG JE, DEVAUCHELLE-PENSEC V et al.: ESSDAI and ESSPRI: EULAR indexes for a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res 2013; 65: 1358-64.
10. De VITA S, QUARTUCCIO L, SALVIN S et al.: Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 2014; 32: 490-4.